Edesa Biotech Inc

STU:RBTQ (Canada)  
(Delisted) € 5.99 (0%) Sep 29
At Loss
P/B:
2.33
Market Cap:
€ 84.34M ($ 90.38M)
Enterprise V:
€ 77.50M ($ 83.05M)
Volume:
-
Avg Vol (2M):
-
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Edesa Biotech Inc ( STU:RBTQ ) from 2013 to Apr 26 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Edesa Biotech stock (STU:RBTQ) PE ratio as of Apr 26 2024 is 0. More Details

Edesa Biotech Inc (STU:RBTQ) PE Ratio (TTM) Chart

To

Edesa Biotech Inc (STU:RBTQ) PE Ratio (TTM) Historical Data

Total 585
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Edesa Biotech PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-09-29 At Loss 2021-07-27 At Loss
2021-09-28 At Loss 2021-07-26 At Loss
2021-09-27 At Loss 2021-07-23 At Loss
2021-09-24 At Loss 2021-07-22 At Loss
2021-09-23 At Loss 2021-07-21 At Loss
2021-09-22 At Loss 2021-07-20 At Loss
2021-09-21 At Loss 2021-07-19 At Loss
2021-09-20 At Loss 2021-07-16 At Loss
2021-09-17 At Loss 2021-07-15 At Loss
2021-09-16 At Loss 2021-07-14 At Loss
2021-09-15 At Loss 2021-07-13 At Loss
2021-09-14 At Loss 2021-07-12 At Loss
2021-09-13 At Loss 2021-07-09 At Loss
2021-09-10 At Loss 2021-07-08 At Loss
2021-09-09 At Loss 2021-07-07 At Loss
2021-09-08 At Loss 2021-07-06 At Loss
2021-09-07 At Loss 2021-07-05 At Loss
2021-09-06 At Loss 2021-07-02 At Loss
2021-09-03 At Loss 2021-07-01 At Loss
2021-09-02 At Loss 2021-06-29 At Loss
2021-09-01 At Loss 2021-06-28 At Loss
2021-08-30 At Loss 2021-06-25 At Loss
2021-08-27 At Loss 2021-06-24 At Loss
2021-08-26 At Loss 2021-06-23 At Loss
2021-08-25 At Loss 2021-06-22 At Loss
2021-08-24 At Loss 2021-06-21 At Loss
2021-08-23 At Loss 2021-06-18 At Loss
2021-08-20 At Loss 2021-06-17 At Loss
2021-08-19 At Loss 2021-06-16 At Loss
2021-08-18 At Loss 2021-06-15 At Loss
2021-08-17 At Loss 2021-06-14 At Loss
2021-08-16 At Loss 2021-06-11 At Loss
2021-08-13 At Loss 2021-06-10 At Loss
2021-08-12 At Loss 2021-06-09 At Loss
2021-08-11 At Loss 2021-06-08 At Loss
2021-08-10 At Loss 2021-06-07 At Loss
2021-08-09 At Loss 2021-06-04 At Loss
2021-08-06 At Loss 2021-06-03 At Loss
2021-08-05 At Loss 2021-06-02 At Loss
2021-08-04 At Loss 2021-06-01 At Loss
2021-08-03 At Loss 2021-05-31 At Loss
2021-08-02 At Loss 2021-05-28 At Loss
2021-07-30 At Loss 2021-05-27 At Loss
2021-07-29 At Loss 2021-05-26 At Loss
2021-07-28 At Loss 2021-05-25 At Loss

Edesa Biotech Inc (STU:RBTQ) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Edesa Biotech Inc
NAICS : 325412 SIC : 3741
ISIN : CA85855A3029
Description
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.